MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer
Open Access
- 1 July 2025
- journal article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2522-2536
Abstract
Background: The microRNA (miR)-200 family is implicated in regulating the immune checkpoint protein programmed death-ligand 1 (PD-L1), a key factor in lung cancer progression and response to immunotherapy. This study investigates the relationship between miR-200 expression and PD-L1 in non-small cell lung cancer (NSCLC), aiming to clarify its potential as a prognostic biomarker and a therapeutic target in immune checkpoint inhibitor (ICI) treatment for NSCLC. Methods: RNA sequencing (RNA-seq) data from public databases were analyzed for correlation between miR-200 family expression and PD-L1 levels in lung cancer. MiR-200 and PD-L1 expression were assessed in lung cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and flow cytometry, respectively. To evaluate functional impact, miR-200 mimics were transfected into cell lines, and PD-L1 protein levels were measured. The influence of interferon gamma (IFN-γ) on miR-200 and PD-L1 expressions in cell lines were examined using RT-qPCR and flow cytometry. Serum samples and tumor biopsies were collected from advanced NSCLC patients before ICI therapy. Serum miR-200a was quantified by Droplet digital polymerase chain reaction (ddPCR), and its correlation with tumor PD-L1 and progression-free survival (PFS) was analyzed. Results: Analysis of RNA-seq data revealed a significant inverse correlation between miR-200 family expression and PD-L1 levels in lung cancer (Pvs. miR-200a-low, 200 days; P=0.008). Conclusions: This study shows that miR-200a regulates PD-L1 expression in NSCLC, affecting immune evasion. Serum miR-200a levels could serve as a non-invasive biomarker to predict PD-L1 expression and immunotherapy outcomes, helping identify patients who may benefit. Modulating miR-200a may also offer a new strategy to reduce PD-L1 in tumors, enhancing immune response.Keywords
This publication has 29 references indexed in Scilit:
- Circulating MicroRNAs in Cancer: Potential and ChallengeFrontiers in Genetics, 2019
- MicroRNA-200a induces apoptosis by targeting ZEB2 in alcoholic liver diseaseCell Cycle, 2017
- MicroRNAs: Novel immunotherapeutic targets in colorectal carcinomaWorld Journal of Gastroenterology, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinomaTumor Biology, 2015
- Circulating miRNAs in cancer: from detection to therapyJournal of Hematology & Oncology, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- MicroRNA‐200b reverses chemoresistance of docetaxel‐resistant human lung adenocarcinoma cells by targeting E2F3Cancer, 2011
- Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung CancerMolecular Cancer Research, 2010